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TheATP-dependent chromatin-remodelingenzymebrahma-related
gene 1 (BRG1) regulates transcription of specific target genes
during embryonic and postnatal development. Deletion of Brg1
from embryonic blood vessels results in yolk sac vascular remodel-
ing defects.We now report thatmisregulation of the canonicalWnt
signaling pathway underlies many Brg1 mutant vascular pheno-
types. Brg1 deletion resulted in down-regulation of several Wnt
receptors of the frizzled family, degradation of the intracellular
Wnt signaling molecule β-catenin, and an overall decrease in Wnt
signaling in endothelial cells. Pharmacological stabilization of β-cat-
enin significantly rescuedBrg1mutant vesselmorphology and tran-
scription of Wnt target genes. Our data demonstrate that BRG1
impacts the canonical Wnt pathway at two different levels in vas-
cular endothelium: through transcriptional regulation of both Wnt
receptor genes and Wnt target genes. These findings establish an
epigenetic mechanism for the modulation of Wnt signaling during
embryonic vascular development.
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Eukaryotes fit a large quantity of DNA into the nuclei of theircells by packaging it into a compact structure called chro-
matin. This packaging presents a barrier to transcription factors
that must access DNA to bring about changes in gene expression.
ATP-dependent chromatin-remodeling complexes alleviate this
problem by temporarily unraveling and reorganizing chromatin,
thereby making DNA more accessible to proteins that are re-
quired for transcription (1, 2). Once considered to be ubiquitous
mediators of transcription, chromatin-remodeling complexes are
increasingly recognized for their specialized functions and spe-
cific genomic targets during development (3, 4). Much of this
specificity has been shown to stem from variations in the subunit
composition of these large, multiprotein complexes (5–8).
One family of ATP-dependent chromatin-remodeling complexes,
the mammalian SWI/SNF (SWItch/Sucrose NonFermentable)-
like complexes, promotes or represses transcription of genes by
increasing or decreasing accessibility of DNA to large transcrip-
tional machinery at specific loci (9, 10). Mammalian SWI/SNF
complexes contain one of two central ATPase catalytic subunits:
brahma (BRM) or brahma-related gene 1 (BRG1).Global deletion
of Brg1 in mice leads to embryonic lethality at peri-implantation
(11). Tissue-specific conditional mutations have elucidated nu-
merous developmental roles for BRG1, including zygotic genome
activation, erythropoiesis, T-cell, cardiac, and neuronal develop-
ment (8, 12–15). Deletion of Brg1 in developing endothelial cells
results in defective yolk sac angiogenesis, although themechanism
by which BRG1 affects vascular development is unclear (16, 17).
The canonical Wnt/wingless signaling pathway is one of several
signaling pathways known to contribute to embryonic vascular de-
velopment (18–20). Canonical Wnt signaling occurs when soluble
Wnt ligands interact with a cell-surface receptor complex con-
sisting of the lipoprotein receptor-related 5/6 (Lrp5/6) proteins and
the seven-transmembrane domain frizzled (Fzd) family proteins
(21). This ligand–receptor interaction stabilizes the intracellular-
signaling molecule β-catenin by inactivating a cytoplasmic de-
struction complex that would otherwise target β-catenin for deg-
radation. Stabilized β-catenin translocates to the nucleus where it
coregulates transcription of Wnt target genes by interacting with
transcription factors in the lymphoid enhancer (LEF)/T-cell factor
(TCF) family. These target genes mediate multiple effects that are
critical for vascular development such as proliferation, differenti-
ation, and morphogenesis (21).
Wnt signaling occurs in numerous embryonic and yolk sac
vessels during midgestation (22), and mutations in various Wnt
signaling components result in vascular abnormalities reminis-
cent of those seen in embryos deleted for endothelial Brg1.
Global deletion of Fzd5 causes lethality at embryonic day 10.75
(E10.75) due to defective yolk sac and placental angiogenesis
(23). In addition, mice that are conditionally deleted of vascular
β-catenin die in utero with defective vascular patterning and in-
creased vascular fragility at E11.5–13.5 (24). Recently, a condi-
tional gain-of-function mutation in β-catenin has been shown to
result in aberrant vascular remodeling and arteriovenous speci-
fication as early as E9.5, demonstrating that early vascular de-
velopment is equally sensitive to over- or underexpression of
β-catenin (22). Although these phenotypes indicate the impor-
tance of Wnt signaling during embryonic vascular development,
little is known about how the pathway is regulated in developing
vessels. We now describe a unique epigenetic mechanism for
modulation of Wnt signaling during early vascular development.
This study demonstrates that BRG1 impacts Wnt signaling at
two levels in endothelial cells: in addition to coregulating tran-
scription of certain Wnt target genes, BRG1 stabilizes β-catenin
by directly mediating expression of multiple frizzled receptors.
Results
Endothelial Deletion of Brg1 Results in Flattening and Thinning of
Yolk Sac Blood Vessels. To determine the role of the SWI/SNF
chromatin-remodeling enzyme BRG1 in vascular development,
we previously deleted a floxed Brg1 allele from embryonic en-
dothelial and hematopoietic cells using a Tie2-Cre transgene
(16). These Brg1 mutant (Brg1fl/fl;Tie2-Cre+/0) embryos die at
E10.5–11 with severe anemia due to failed transcription of em-
bryonic β-globins and subsequent apoptosis of embryonic eryth-
rocytes. In addition, Brg1 mutants display yolk sac-specific
angiogenesis defects manifesting in vascular patterning abnor-
malities by E9.5. Subsequent analysis of Brg1-deleted yolk sac
vessels revealed exaggerated abnormalities at E10.5 preceding
embryonic lethality (Fig. 1). At this time, Brg1 mutant yolk sac
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vessels were uniformly thin, and many vessels failed to in-
terconnect, resulting in a tapering, dead-end vasculature (Fig.
1D). Comparable vascular thinning and disconnectedness were
not observed in the mutant embryonic head or intersomitic
vessels (Fig. S1A), highlighting the specificity of these Brg1 mu-
tant vascular phenotypes for the extraembryonic yolk sac.
In addition to the thinning of yolk sac microvasculature, Brg1
mutants underwent thinning of vitelline vessels—the major ves-
sels connecting the embryo to the yolk sac. Vitelline vessel
diameters were measured at the first branch point as the vessels
entered the yolk sac, and significant thinning was observed in Brg1
mutants starting at E9.5 (Fig. S1B). Pan-endothelial markers were
expressed at comparable levels in primary endothelial cells iso-
lated from E10.5 control and mutant yolk sacs (Fig. S1C). Like-
wise, proliferation rates and apoptosis were comparable in
control and Brg1 mutant yolk sac endothelium (Fig. S1 D and E).
However, Brg1 mutant yolk sac vessels were deflated by E9.5
when assessed histologically, whereas control yolk sac vessels had
inflated luminal spaces with numerous circulating embryonic
blood cells (Fig. 1E and F). The flattening of Brg1mutant yolk sac
vessels was further verified by transmission electron microscopy.
By E10.5, mutant blood vessels were tightly wrapped around
circulating embryonic blood cells (Fig. 1H and J), whereas control
vessels maintained an abundant luminal space (Fig. 1 G and I).
Importantly, discontinuities were observed in the endothelial cell
lining of mutant yolk sac vessels (Fig. 1J, arrow). These dis-
continuities were too small for blood cells to hemorrhage from
mutant vessels but were large enough for plasma leakage to occur.
Such plasma leakage could account for the vascular flattening and
microvascular thinning observed in Brg1 mutant yolk sac vessels
(Fig. 1 F and D). Likewise, plasma leakage from yolk sac vessels
may explain the hyper-inflated and distended yolk sac cavities that
were consistently associated with mutant embryos (Fig. 1B).
Wnt Signaling Is Down-Regulated in Brg1 Mutant Yolk Sac Endo-
thelium. The Brg1 mutant phenotypes of vitelline vessel thin-
ning, endothelial cell discontinuity, and plasma leakage are sim-
ilar to phenotypes observed in embryos with deletion of vascular
β-catenin, a key component of the canonical Wnt signaling
pathway (24). Likewise, the yolk sac-specific vascular abnormal-
ities in Brg1 mutants are reminiscent of yolk sac-specific vascular
phenotypes observed in mutants for the Wnt receptor Fzd5 (23).
To investigate the possibility that Brg1 mutant yolk sac vascular
phenotypes result from a down-regulation of Wnt signaling in the
absence of BRG1, we crossed a Wnt signaling reporter mouse
with our Brg1 mutants. The

β-catenin-activated transgene driving
expression of the nuclear β-galactosidase reporter (BAT-gal) has
been successfully used to visualize Wnt signaling in developing
embryonic and postnatal vasculature (22, 25, 26). We found that
endogenous Wnt signaling is evident at low levels in control yolk
sac endothelium at E10.5 (Fig. 2A) but is undetectable in Brg1
mutant yolk sac endothelium (Fig. 2B), providing strong evidence
that Brg1 depletion results in decreased Wnt signaling in vivo.
To further investigate the status of downstream Wnt signaling
in Brg1 mutant yolk sac endothelium, we designed a custom real-
time quantitative PCR (qPCR) array containing 28 direct Wnt
target genes. We found 70% of these genes down-regulated in
primary Brg1 mutant endothelial cells isolated from E10.5 yolk
sacs (Fig. 2C). To support these array data, we selected five of
these down-regulated Wnt target genes for validation by qPCR.
Transcript levels of the Wnt targets Axin2, T, CyclinD1, Wisp1,
andMyc were significantly reduced in mutant yolk sac endothelial
cells (Fig. 2D). This decrease in Wnt target gene expression
corresponds well with the loss ofWnt signaling observed using the
BAT-gal reporter transgene and suggests that BRG1 influences
Wnt signaling in the yolk sac during vascular development.
BRG1 Depletion Results in a Decrease in β-Catenin Protein Levels in
Endothelial Cells. Given the phenotypic similarities between our
vascular Brg1 mutants and the previously described vascular
β-cateninmutants (24), we sought to determine whether β-catenin
expression was altered upon loss of BRG1. We used Brg1-specific
siRNA oligos to knock down BRG1 expression in the C166 mu-
rine yolk sac endothelial cell line (27). Immunoblots revealed
a significant reduction in β-catenin protein levels following BRG1
knockdown (Fig. 2E and Fig. S2B). Furthermore, immunofluo-
rescent staining of control and BRG1-depleted C166 endothelial
cells and of primary endothelial cells isolated from control and
mutant yolk sacs demonstrated a modest decrease in β-catenin
protein (Fig. S2 A and C).
In addition to its role in nuclear Wnt signaling, β-catenin also
plays an important role in stabilization of adherens junctions—
multiprotein complexes that mediate homotypic endothelial cell
adhesion and control endothelial cell permeability (28). Because
we had observed discontinuities in Brg1 mutant yolk sac endo-
thelial cells by electron microscopy (Fig. 1J), we investigated the
expression of adherens junction proteins.Weobserved diminished






















































Fig. 1. Brg1 deletion results in vascular abnormalities in extraembryonic
yolk sacs. (A and B) E10.5 littermate control Brg1fl/fl (A) and mutant Brg1fl/fl;
Tie2-Cre+/0 embryos (B). (Scale bars: 1 mm.) (C and D) Anti-PECAM1 staining
on histological sections of E10.5 yolk sacs reveal thinner vessels in mutants
(D) compared with controls (C). (Scale bars: 100 μm.) (E and F) Hematoxylin
and eosin (H&E)-stained paraffin sections of E9.5 littermate control Brg1fl/fl
(E) and mutant Brg1fl/fl;Tie2-Cre+/0 (F) yolk sac vessels. Vessels are flattened
in mutants (F) compared with controls (E). Arrows indicate embryonic blood
cells. (Scale bars: 50 μm.) (G–J) Transmission electron micrographs (TEM) of
control Brg1fl/fl (G and I) versus mutant Brg1fl/fl;Tie2-Cre+/0 (H and J) yolk sac
vessels reveal discontinuities in the mutant endothelial lining (arrow in J).
MC, mural cell; VE, visceral endoderm; BC, blood cell; EC, endothelial cell.
(Scale bars: 5 μm.)














endothelial cells (Fig. S2A). However, we did not detect any
changes in α-catenin, desmoplakin, or VE-cadherin (Fig. S2B),
indicating that adherens junctions are not grossly disrupted upon
BRG1 depletion.
Because β-catenin protein levels were reduced with BRG1
depletion, we investigated whether β-catenin is a direct tran-
scriptional target of BRG1. We measured β-catenin transcript
levels in BRG1-depleted C166 endothelial cells and in Brg1
mutant primary yolk sac endothelial cells, but we detected no
down-regulation of β-catenin transcription (Fig. 2F and Fig.
S2D). These results indicate that β-catenin is not a direct tran-
scriptional target of BRG1 and suggest that the decreased
β-catenin levels observed in the absence of BRG1 are due to
protein degradation.
Pharmacological Rescue of β-Catenin Degradation Significantly
Improves Brg1 Mutant Yolk Sac Vessel Morphology. In the absence
of Wnt signaling, cytoplasmic β-catenin is phosphorylated by
glycogen synthase kinase-3β (GSK-3β) and targeted for degra-
dation via the ubiquitin–proteasome pathway (21). Lithium
chloride (LiCl) is a known inhibitor of GSK-3β, and because it
prevents β-catenin degradation, LiCl has been used extensively
to promote Wnt signaling in vitro, including in cultured endo-
thelial cells (29, 30). Administration of LiCl to pregnant mice
rescues embryos with cardiac defects due to mutation of Wnt2
(31). We attempted a similar in vivo rescue of Brg1 mutant yolk
sac vasculature to determine the degree to which β-catenin
degradation contributes to vascular abnormalities.
Following 2 d of injection with LiCl, we dissected and immu-
nostained extraembryonic yolk sacs at E10.5 to assess the mor-
phology and patterning of mutant blood vessels. We observed
significant rescue of vessel morphology in Brg1 mutant yolk sacs
that had been exposed to LiCl (Fig. 3 D, H, and I and Fig. S3D).
LiCl-treated Brg1 mutant microvasculature was thicker and more
interconnected than microvasculature from mutants treated with
NaCl as a negative control (compare B andD in Fig. 3). Likewise,
Brg1 mutant vitelline vessel diameters were partially rescued by
LiCl treatment (Fig. 3 H and I). Mutant vitelline vessel diameters
were 16% of control diameters with NaCl treatment and im-
proved to 55% of control diameters with LiCl treatment (Fig. 3I).
Furthermore, mutant yolk sacs displayed a modest rescue of
vascular flattening following LiCl treatment, as assessed by his-
tology and light microscopy (Fig. S3D).
Importantly, LiCl treatment did not rescue the severe anemia
that we previously described in Brg1 mutants (16). Brg1 mutant
embryos and yolk sacs treated with LiCl or NaCl displayed
a comparable pallor by gross observation and deficit of embry-
onic blood cells (Fig. S3 E–I). This finding settles a point of
debate as to the impact of blood loss on vascular patterning in
Brg1 mutants. Although alterations in blood flow biomechanics
may contribute partially to Brg1 vascular phenotypes, our LiCl-
mediated rescue of vessel patterning and morphology clearly
indicates that a paucity of blood is not solely responsible for the
mutant phenotypes. Altogether, these in vivo experiments pro-
vide evidence that deficient levels of β-catenin contribute to Brg1
mutant yolk sac vascular phenotypes.
Pharmacological Rescue of β-Catenin Degradation Restores Tran-
scription of Selected Wnt Target Genes. To determine whether
Wnt signaling is rescued in Brg1mutant yolk sac vasculature upon
LiCl treatment, we analyzed embryos carrying the BAT-gal Wnt
signaling reporter transgene. LiCl dramatically rescued reporter
activity in Brg1mutant yolk sac endothelial cells (Figs. 3K and Fig.
S4H), which is consistent with the rescue of vascular morpho-
logical abnormalities in Brg1 mutant yolk sacs. Interestingly, LiCl
also rescued reporter activity in Brg1mutant placental endothelial
cells, which underwent a striking loss of reporter activity in the
absence of treatment (Fig. S4 I–N). However, we did not observe
either placental abnormalities in Brg1 mutants or gross changes
to placental vasculature with LiCl treatment.
We also isolated endothelial cells from control versus mutant
yolk sacs for quantitative assessment ofWnt target genes that were
down-regulated in untreatedBrg1mutants (Fig. 2D). Interestingly,
of the five Wnt target genes that we assessed, Axin2 and CyclinD1
were rescued to normal transcript levels with LiCl treatment,
whereas T, Wisp1, and Myc remained down-regulated (Fig. 3L).
We hypothesized that the genes remaining down-regulated fol-
lowing LiCl treatment might require BRG1 for coregulation of
their transcription. In support of this hypothesis, chromatin im-
munoprecipitation (ChIP) assays indicated that BRG1 associates
with the promoter region of Wisp1 and that it is a direct target of
BRG1 in endothelial cells (Fig. 3M). Previous studies have shown
that BRG1 and β-catenin coregulateWnt signaling in nonvascular
cells by mediating chromatin remodeling and transcriptional ac-
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Fig. 2. Wnt signaling is down-regulated, and β-catenin protein is degraded
in Brg1 mutants. (A and B) Embryos were crossed onto the BAT-gal Wnt
reporter line for detection of Wnt signaling activity. E10.5 X-gal–stained yolk
sacs were cryosectioned and counterstained with eosin. Blue arrowhead,
reporter-positive endothelium; white arrowhead, reporter-negative endo-
thelium. (Scale bars: 50 μm.) (C and D) Endothelial cells from littermate
control and mutant yolk sacs were isolated, RNA was purified, and cDNA was
synthesized. (C) Samples were processed for qPCR using a custom-designed
array containing 28 Wnt target genes (Fig. S5A). Data from four indepen-
dent experiments were compiled using SABiosciences Excel-based data anal-
ysis. (D) qPCR was carried out for five Wnt target genes (Axin2, T, CyclinD1,
Wisp1, and Myc). Errors represent ±SEM from six independent experiments,
and significant differences between littermate controls and mutants were
calculated using a two-tailed Student’s t test (**P < 0.005). (E and F) C166
cells were transfected with nonspecific (NS) or Brg1-specific siRNA for 48 h.
(E) Protein samples were subjected to Western blot analysis with antibodies
that recognize BRG1, β-catenin, or GAPDH. (F) RNA was isolated, cDNA was
synthesized, and qPCR for Brg1 or β-catenin was carried out. Errors represent
±SEM from four independent experiments, and significant differences be-
tween NS or Brg1-specific siRNA-transfected cells were calculated using a
two-tailed Student’s t test (**P < 0.005).
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BRG1 similarly coregulates transcription of a subset ofWnt target
genes in vascular endothelial cells.
BRG1 Mediates Transcription of Fzd Receptors. Because we found
that β-catenin protein levels, but not transcript levels, were re-
duced upon depletion of BRG1, and because β-catenin is de-
graded in the absence of Wnt signaling (21), we decided to
investigate the relationship between BRG1 and theWnt signaling
pathway upstream of β-catenin. Using a Wnt pathway qPCR ar-
ray, we identified several Wnt receptor Fzd family members that
were significantly down-regulated when BRG1 was knocked down
in C166 yolk sac endothelial cells (Fig. S5B). We verified these
data using qPCR with gene-specific primers and found that the
transcript levels of Fzd2, -3, -4, -5, -6, -7, and -8 were significantly
reduced upon BRG1 knockdown (Fig. 4A). Importantly, we
performed qPCR on primary yolk sac endothelial cells isolated
from control and mutant embryos and confirmed that the tran-
script levels of Fzd2, -3, -4, -7, and -8 were down-regulated in
mutant cells (Fig. S5C). Fzd5 and Fzd6 were not significantly al-
tered in the mutant primary endothelial cells, although it is pos-
sible to attribute this discrepancy to a lack of preparation pu-
rity compared with the yolk sac-derived C166 stable endothelial
cell line. Nevertheless, we conclude that the significant down-
regulation of several Fzd receptors upon deletion of Brg1 may
contribute to the decrease in Wnt signaling observed in our mu-
tant yolk sac vasculature.
Because the transcript levels of several Fzd receptors were
reduced with BRG1 deletion, we were interested in determining
whether these Fzd genes are direct targets of BRG1. ChIP assays
indicate that BRG1 associates with the promoter region of nu-
merous Fzd receptor genes in C166 endothelial cells (Fig. 4B).
We conclude that BRG1 epigenetically modulates vascular Wnt
signaling through direct association and subsequent transcrip-
tional activation of the Fzd family of Wnt receptors. Our data
demonstrate a unique mechanism by which BRG1 influences the
canonical Wnt pathway upstream of β-catenin.
Discussion
Wnt signaling has been gathering prominence in the field of




































































































Fig. 3. Inhibition of β-catenin degradation with LiCl treatment rescues
vascular anomalies and Wnt signaling in Brg1 mutant yolk sacs. (A–H)
Pregnant mice were injected with 400 mg/kg NaCl (A and B, E and F) or LiCl
(C and D, G and H) on E8.5 and E9.5. Embryos were dissected at E10.5, and
littermate control Brg1fl/fl (A, C, E, G) and mutant Brg1fl/fl;Tie2-Cre+/0 (B, D, F,
H) yolk sacs were whole-mount immunostained with antibodies against
PECAM1. (A–D) (Scale bars: 50 μm.) (E–H) (Scale bars: 100 μm.) (I) Mean vi-
telline vessel (V. V.) diameter measurements from 10 control and 3 mutant
yolk sacs treated with NaCl or from 12 control and 4 mutant yolk sacs treated
with LiCl. Errors were calculated as ±SEM, and a two-tailed Student’s t test
was used to detect statistical differences in controls versus mutants or be-
tween NaCl- and LiCl-treated mutants (*P < 0.05; **P < 0.005). (J and K)
Embryos carrying the BAT-gal Wnt reporter transgene were treated in utero
with LiCl for 2 d before dissection at E10.5. X-gal–stained yolk sacs were
cryosectioned and counterstained with eosin. Blue arrowheads, reporter-
positive endothelium. (Scale bars: 50 μm.) (L) Endothelial cells from LiCl-
treated littermate control and mutant yolk sacs were isolated, RNA was
purified, cDNA was synthesized, and qPCR was carried out for Wnt target
genes (Axin2, T, CyclinD1, Wisp1, and Myc). Errors represent ±SEM from six
independent experiments, and significant differences between littermate
controls and mutants were calculated using a two-tailed Student’s t test
(**P < 0.005). (M) Chromatin immunoprecipitation assays were carried out
using isotype-matched antibodies against BRG1, acetylated histone H3
(AcH3) as a positive control, or a polyhistidine epitope tag (His) as a negative
control. DNA was isolated and amplified by qPCR to determine whether
BRG1 and AcH3 were associated with the promoter region of Wisp1. Data
from four independent experiments were combined and are presented as
the percentage (%) of input ±SEM; significant differences were calculated

































































Fig. 4. BRG1 mediates expression of multiple Fzd receptors. (A) C166 cells
were transfected with nonspecific (NS) or Brg1-specific siRNA for 48 h. RNA
was isolated, cDNA was synthesized, and qPCR for Fzd1-8 was performed.
Errors represent SEM, and significant differences between NS or Brg1-specific
siRNA-transfected cells were calculated using a two-tailed Student’s t test
(**P < 0.005). (B) Endogenous chromatin from C166 cells was immunopreci-
pitated using isotype-matched antibodies against BRG1, acetylated histone
H3 (AcH3) as a positive control or a polyhistidine epitope tag (His) as a neg-
ative control. DNAwas isolated and amplified by qPCR to determine whether
BRG1 and AcH3 were associated with the promoter regions of Fzd1, -4, -5, -6,
or -8. A region upstream of the Fzd5 promoter was used as a negative control,
and the ADAMTS1 promoter acted as a positive control gene region (17).
Data from four independent experiments were combined and are presented
as the percentage (%) input ±SEM; significant differences were calculated
using a two-tailed Student’s t test (*P < 0.05).














blood vessel patterning, specification, and angiogenesis (22, 25,
34, 35). However, a mechanistic understanding of Wnt signaling
regulation in developing vasculature has been elusive. We now
present evidence for epigenetic modulation of the Wnt pathway
during blood vessel development by the chromatin-remodeling
enzyme BRG1. Importantly, we demonstrate that BRG1 impacts
the Wnt pathway at two different levels: through transcriptional
regulation of multiple Fzd receptors and of Wnt target genes.
Moreover, we show that vascular deletion of Brg1 results in ab-
errant yolk sac angiogenesis, which is partially rescued by stabi-
lization of β-catenin (Fig. 5).
β-Catenin has two cellular roles: nuclear β-catenin is a key
transcriptional activator of Wnt target genes, and cell-surface
β-catenin helps anchor the transmembrane adhesion protein VE-
cadherin to the actin cytoskeleton for adherens junction stabili-
zation (36). We predict that Brg1 mutant yolk sac phenotypes are
predominantly influenced by down-regulated β-catenin signaling
rather than by junctional defects. We detect a loss of Wnt re-
porter activity in Brg1 mutant yolk sac endothelium in vivo,
suggesting that nuclear β-catenin signaling is compromised in the
absence of BRG1. We also demonstrate that a number of Wnt
target genes are down-regulated upon Brg1 deletion in primary
yolk sac endothelial cells. Taken together, these data indicate
that BRG1 modulates nuclear Wnt signaling in yolk sac vascu-
lature. Nevertheless, we do observe a reduction of β-catenin at
the cell surface of cultured endothelial cells depleted of BRG1.
Although we do not see changes in expression of other adherens
junction proteins in these cells, we cannot exclude the possibility
that down-regulated junctional β-catenin might contribute to
Brg1 mutant yolk sac phenotypes.
β-Catenin was previously shown to recruit BRG1 for co-
regulation of Wnt target gene transcription in nonvascular cells
(32, 33). Our studies demonstrate that a subset of Wnt target
genes are similarly coregulated by BRG1 in endothelial cells.
The Wnt target genes Wisp1, T, and Myc were down-regulated in
Brg1 mutant endothelium—even after stabilization of β-catenin
with LiCl treatment—implying that both β-catenin and BRG1
are necessary for their transcription. However, BRG1 is not re-
quired for coregulation of all Wnt target genes in endothelial
cells because LiCl treatment rescued expression of Axin2 and
CyclinD1 in Brg1 mutants. Perhaps these and other Wnt targets
that do not require BRG1 for transcriptional regulation account
for the partial but significant rescue of Brg1 mutant vascular
phenotypes following β-catenin stabilization with LiCl.
The yolk sac specificity of the Brg1 mutant phenotypes that we
have described is intriguing, given that Wnt signaling occurs
concurrently in both embryonic and yolk sac vessels at midg-
estation (22) and that β-catenin vascular mutants display both
embryonic and yolk sac vascular abnormalities (24). One expla-
nation for this phenotypic specificity may lie in the Fzd genes that
are targeted by BRG1. Global deletion of Fzd5 results in yolk
sac-specific vascular phenotypes that are highly reminiscent of
those seen in Brg1 mutants (23). We saw Fzd5 down-regulated
following BRG1 depletion in endothelial cells, although its ex-
pression was not completely eliminated. Because Fzd5+/− em-
bryos are phenotypically normal (23), our data indicate that
partial down-regulation of Fzd5 is not solely responsible for Brg1
mutant yolk sac phenotypes. However, much functional re-
dundancy is assumed to exist between the 10 mammalian Fzd
receptors (21). We speculate that partial down-regulation of
several Fzd receptors in the yolk sac creates a Wnt-signaling
environment comparable to complete deletion of Fzd5. Little is
known about the regulation of Fzd signaling, but our data pro-
vide evidence for the coordinated regulation of multiple Fzd
receptors by a single chromatin-remodeling enzyme.
Another explanation for the yolk sac specificity of our Brg1
mutant phenotypes may lie in the functional redundancy be-
tween various chromatin-remodeling complexes. We previously
assessed embryos deficient for both vascular Brg1 and the alter-
native SWI/SNF ATPase Brm, but the double mutants show no
exacerbation of vascular phenotypes over those seen in the single
Brg1 mutants (16). Therefore, other chromatin-remodeling com-
plexes outside the SWI/SNF family may compensate for loss of
Brg1 in embryonic vasculature and in non-Wnt signaling pathways
in the yolk sac.
The significant rescue of Brg1 vascular mutant phenotypes by
pharmacological stimulation of the Wnt signaling pathway pro-
vides convincing evidence that BRG1 epigenetically modifies
Wnt signaling during yolk sac vascular development. One out-
standing question is whether BRG1 plays a similar role at later
developmental time points and during pathological angiogenesis.
Wnt signaling regulates angiogenesis in the central nervous sys-
tem during development of the blood–brain barrier (25, 34, 35)
and in the retina during diabetic retinopathy (37). Induction of
Brg1 vascular deletion at later time points and following patho-
logical challenge will be required for a more comprehensive
understanding of how BRG1 spatially and temporally influences
vascular Wnt signaling under various angiogenic conditions.
Materials and Methods
Mice. Brg1-floxed mice (Brg1fl/fl) (14), Tie2-Cre transgenic mice (38), and
BAT-gal transgenic mice (39) were maintained on a mixed genetic back-
ground at the Oklahoma Medical Research Foundation animal facil-
ity. All animal use protocols were approved by the Institutional Animal
Care and Use Committee. See SI Materials and Methods for genotyping
information.
Cell Culture and Transfections. C166 murine yolk sac endothelial cells (ATCC,
no.CRL-2581) were maintained on Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FBS. Cells were transfected with 100 nM
Brg1 siGENOME SMARTpool or nontargeting control siRNA (Thermo Scien-
tific, catalog nos. M-041135–01 and D-001210–01, respectively) using Lip-
ofectamine 2000 (Invitrogen) in serum-free OptiMEM (Invitrogen). After
48 h, cells were harvested in Laemmli buffer (62.5 mM Tris, pH 6.8, 10%
glycerol, 5% SDS, 0.01% bromophenol blue) for Western blot analysis or
TRIzol (Invitrogen) for transcript analysis.
Western Blot. Total protein was harvested from siRNA-transfected C166 cells,
fractionated in a 9% SDS polyacrylamide gel, and transferred to a PVDF
membrane for Western blot analysis with antibodies to BRG1 (Santa Cruz
Biotechnology, sc-17796), active β-catenin (Millipore, 05-665), α-catenin
(BD Transduction Laboratories, 610193), desmoplakin (Abcam, ab16434),
VE-cadherin (BD Pharmingen, 550548), and GAPDH (Sigma, G9545). Band
intensity was determined for each protein using ImageJ software (National
Institutes of Health).
Primary Endothelial Cell Isolation. Yolk sacs from E10.5 embryos were
digested with collagenase-DNase solution (1.5 mg/mL collagenase, 25 mg/
mL DNase, 25 mM Hepes in DMEM) for 30 min at 37 °C. Cells were washed
once with PBS/0.1% BSA and resuspended in DMEM. Dynabeads conju-










































Fig. 5. Model for how BRG1 impacts Wnt signaling during yolk sac vascular
development. BRG1 epigenetically modifies Wnt signaling at two levels—
through transcriptional regulation of multiple Fzd receptor genes and
through subsequent association with β-catenin for regulation of certain
downstream Wnt target genes. The dashed line indicates that BRG1 is not
required for coregulation of all Wnt target genes in endothelial cells.
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samples were incubated for 30 min at 4 °C with rotation. Immunopreci-
pitated cells were washed once with PBS/0.1% BSA and eluted in TRIzol
(Invitrogen).
qPCR. To analyze transcript levels, total RNA from siRNA-transfected C166
cells or from primary yolk sac endothelial cells was isolated using TRIzol
(Invitrogen) according to the manufacturer’s instructions. The DNA-free kit
(Ambion) was used to digest any contaminating DNA. cDNA was prepared
using the MultiScribe Reverse Transcriptase kit (Applied Biosystems), and
real-time quantitative PCR was performed using SYBR Green PCR master
mix (Applied Biosystems) and the ABI7000 thermocycler (ABI) with gene-
specific primers.
ChIP. ChIP was performed as described (16), with modifications (SI Materials
and Methods).
Yolk Sac Staining. Whole-mount yolk sac immunostaining and X-gal staining
for β-galactosidase activity were performed as described (16), with mod-
ifications (SI Materials and Methods).
LiCl Injections. LiCl or NaCl (400 mg/kg, dissolved in water) was injected in-
traperitoneally into pregnant females at E8.5 and E9.5. Embryos were har-
vested for yolk sac vascular analysis or endothelial cell isolation at E10.5.
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